Elite in Gaucher Disease Type 1

Timothy M. Cox

Cambridge, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Gaucher Disease Type 1
Cambridge, ENG, GB 
OverviewLocationsClinical Research

Overview

Timothy Cox practices in Cambridge, United Kingdom. Mr. Cox is rated as an Elite expert by MediFind in the treatment of Gaucher Disease Type 1. His top areas of expertise are Gaucher Disease, Gaucher Disease Type 1, Farber Lipogranulomatosis, Tay-Sachs Disease, and Splenectomy.

His clinical research consists of co-authoring 104 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Gaucher Disease Type 1.

Gender
Male

Locations

Cambridge, ENG CB20QQ, United Kingdom
Other Locations
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Predictive Measures to Stratify Clinical Outcomes in Children and Adults With Gaucher Disease and Responses to Specific Therapies
Predictive Measures to Stratify Clinical Outcomes in Children and Adults With Gaucher Disease and Responses to Specific Therapies
Enrollment Status: Recruiting
Publish Date: August 06, 2024
Intervention Type: Other
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
View 1 Less Clinical Trial

102 Total Publications

Treatment preferences of adult patients with hereditary fructose intolerance: A discrete choice experiment.
Treatment preferences of adult patients with hereditary fructose intolerance: A discrete choice experiment.
Journal: Molecular genetics and metabolism
Published: April 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cox's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile